News Releases

Applications Now Open for Bristol Myers Squibb Canada’s Quality Improvement Initiative in Immuno-oncology

Applications are open to all healthcare organizations in Canada. Healthcare Professionals actively involved in the delivery of healthcare to cancer patients within a Canadian hospital are eligible to apply on behalf of their Institution.

BMS

03/06/21

MONTREAL, QUEBEC – June 3, 2021 – Today, Bristol Myers Squibb (BMS) Canada announces the launch of the Quality Improvement Initiative in Immuno-oncology (QI3). Now open for applications, the goal of the QI3 sponsorship is to identify and support system-wide changes to help hospitals, healthcare professionals and patients receiving treatment with immune checkpoint inhibitors adapt to the growing use of immuno-oncology (I-O) agents.

 

Unlike traditional cancer therapies that target tumours directly, I-O activates the body's own immune system to help recognize and attack cancer cells.[1] While still a lesser-known class of anti-cancer therapy, over the last 10 years I-O therapy has increased in use from less than five per cent in metastatic cancer patients to almost 50 per cent.[2]

 

The unique profile of I-O therapy requires differentiated patient management approaches from that of standard chemotherapy or targeted therapies. The launch of QI3 is intended to support new, sustainable initiatives that will improve the delivery of healthcare to patients on I-O therapies.

 

“Bristol Myers Squibb has long been a leader in the I-O space, bringing the first I-O therapy to Canadians in 2012,” says Al Reba, General Manager, BMS Canada. “The QI3 program is an extension of our commitment to improving how cancer is treated, making long-term survival a possibility for more patients. As a company, we are dedicated to supporting innovative programs that directly impact the quality of life of patients receiving I-O therapy.”

 

To learn more about the program and download the application form, interested applicants should visit the BMS website.

 

About the Quality Improvement Initiative in Immuno-oncology

·       The BMS QI3 is open to all health care organizations in Canada. Healthcare professionals employed by or holding a position in a hospital, and actively involved in the delivery of health care to cancer patients treated with immune checkpoint inhibitors are eligible to apply on behalf of their Institution.

 

·       Eligible professionals include, but are not limited to: 

o   Physicians (all disciplines)

o   Nurses and all nursing-affiliated personnel 

o   Allied-health professionals

o   Other hospital-based professionals that participate in or who have an interest in the delivery of care to cancer patients

·       Projects up to $50,000 will be considered.

·       Number of projects funded depends on number of applications received.

·       Only those projects that have the potential to transfer knowledge and experience gained, to other disease sites, healthcare teams or hospitals will be considered.

·       Applicants should download and complete the QI3 Application Form and return the completed form to QI3@bms.com by September 30, 2021.

 

About Bristol Myers Squibb Canada

Bristol Myers Squibb Canada Co. is an indirect wholly-owned subsidiary of Bristol Myers Squibb Company, a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb global operations, visit www.bms.com. Bristol Myers Squibb Canada Co. delivers innovative medicines for serious diseases to Canadian patients in the areas of cardiovascular health, oncology, hematology and immunology. For more information, please visit www.bms.com/ca.

 

 

-30-

 

For media requests please contact:

Rachel Yates
Lead, Corporate Affairs
Bristol Myers Squibb Canada
rachel.yates@bms.com

 

References:

 

[1] Canadian Cancer Society. Immunotherapy. https://www.cancer.ca/en/cancer-information/diagnosis-and-treatment/chemotherapy-and-other-drug-therapies/immunotherapy/?region=on. Accessed May 26, 2020.

[2] Haslam A and Prasad V, JAMA Network Open 2019